# Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19

> **NCT05166876** · PHASE2 · TERMINATED · sponsor: **Clear Creek Bio, Inc.** · enrollment: 26 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Brequinar Sodium
- **DRUG:** Dipyridamole 75 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05166876
- **Lead sponsor:** Clear Creek Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-01
- **Primary completion:** 2022-06-04
- **Final completion:** 2022-06-04
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Low prevalence of COVID-19 in India led to lack of eligible subjects.
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05166876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05166876, "Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05166876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*